A Glimpse Into The Expert Outlook On HealthEquity Through 13 Analysts
Ratings for HealthEquity (NASDAQ:HQY) were provided by 13 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 10 | 0 | 0 | 0 |
| Last 30D | 1 | 5 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 2 | 5 | 0 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $101.62, a high estimate of $110.00, and a low estimate of $92.00. Observing a 6.77% increase, the current average has risen from the previous average price target of $95.18.
Interpreting Analyst Ratings: A Closer Look
The standing of HealthEquity among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Stan Berenshteyn | Wells Fargo | Raises | Overweight | $107.00 | $105.00 |
| Alexander Paris | Barrington Research | Raises | Outperform | $105.00 | $100.00 |
| Sean Dodge | RBC Capital | Maintains | Outperform | $92.00 | $92.00 |
| Allen Lutz | B of A Securities | Raises | Buy | $105.00 | $97.00 |
| Constantine Davides | JMP Securities | Raises | Market Outperform | $105.00 | $101.00 |
| Mark Marcon | Baird | Raises | Outperform | $104.00 | $98.00 |
| Constantine Davides | JMP Securities | Announces | Market Outperform | $101.00 | - |
| Anne Samuel | JP Morgan | Raises | Overweight | $108.00 | $86.00 |
| Scott Schoenhaus | Keybanc | Raises | Overweight | $95.00 | $85.00 |
| Alexander Paris | Barrington Research | Announces | Outperform | $100.00 | - |
| David Larsen | BTIG | Raises | Buy | $110.00 | $100.00 |
| Sean Dodge | RBC Capital | Raises | Outperform | $92.00 | $90.00 |
| Allen Lutz | B of A Securities | Raises | Buy | $97.00 | $93.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to HealthEquity. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of HealthEquity compared to the broader market.
- Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into HealthEquity's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on HealthEquity analyst ratings.
All You Need to Know About HealthEquity
HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.
Breaking Down HealthEquity's Financial Performance
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: HealthEquity displayed positive results in 3 months. As of 31 January, 2024, the company achieved a solid revenue growth rate of approximately 12.21%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: HealthEquity's net margin excels beyond industry benchmarks, reaching 10.05%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): HealthEquity's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.31% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): HealthEquity's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.84% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: HealthEquity's debt-to-equity ratio is below the industry average at 0.46, reflecting a lower dependency on debt financing and a more conservative financial approach.
Analyst Ratings: What Are They?
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.